TAB2

Across TCGA pan-cancer cohorts, TAB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAB2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TAB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TAB2 expression acts as an unfavorable survival marker.

PDAC, HNSC, and GBM are the cancer types where TAB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	19	view →
HNSC	OS	Tertile	III,IV	0.758	0.966	.024	6	view →
GBM	OS	Quartile	All	0.424	0.754	.004	4	view →
LSCC	DFS	Median	II,III,IV	0.572	0.790	.033	3	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TAB2–PDAC (DFS)

Open the PDAC breakdown →